Table 1 Clinical Trials using CRISPR/Cas9 technology in Cancer Immunotherapy
From: GMP-manufactured CRISPR/Cas9 technology as an advantageous tool to support cancer immunotherapy
NCT Number | Study Design | Target Gene | Phases | Cell Type | Tumor Type |
|---|---|---|---|---|---|
NCT04438083 | A Safety and Efficacy Study Evaluating CTX130 | TRAC; β2M; CD70 | Phase 1 | CAR T-Cells | Renal Cell Carcinoma |
NCT04417764 | TACE Combined With PD-1 Knockout Engineered T Cell | PD-1 | Phase 1 | Engineered T-Cells | Hepatocellular Carcinoma |
NCT04244656 | A Safety and Efficacy Study Evaluating CTX120 | TCR; MHC I | Phase 1 | CAR T-Cells | Multiple Myeloma |
NCT02793856 | PD-1 Knockout Engineered T Cells | PD-1 | Phase 1 | Engineered T-Cells | Metastatic Non-small Cell Lung Cancer |
NCT03081715 | PD-1 Knockout Engineered T Cells | PD-1 | Completed | Engineered T-Cells | Esophageal Cancer |
NCT03545815 | CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells | PD-1; TCR | Phase 1 | CAR T-Cells | Multiple solid tumor |
NCT03398967 | Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy | TRAC; CD52 | Phase 1/ Phase 2 | CAR T-Cells | B-cell Acute Lymphoblastic Leukemia |
NCT02867332 | PD-1 Knockout Engineered T Cells | PD-1 | Phase 1 | Engineered T-Cells | Renal Cell Carcinoma |
NCT05812326 | PD-1 Knockout Anti-MUC1 CAR-T Cells | PD-1 | Phase 1/ Phase 2 | Engineered T-Cells | Breast Cancer |
NCT02867345 | PD-1 Knockout Engineered T Cells | PD-1 | Unknown | Engineered T-Cells | Prostate Cancer |
NCT05662904 | Genetic Ablation of CD33 in HSC | CD33 | Phase 1 | Hematopoietic Stem Cells | Acute Myeloid Leukemia |
NCT03044743 | PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies | PD-1 | Phase 1/ Phase 2 | Engineered T-Cells | Gastric Carcinoma; Nasopharyngeal Carcinoma; T cell Lymphoma; Adult Hodgking |
NCT03057912 | TALEN and CRISPR/Cas9 in the Treatment of HPV-related Cervical Intraepithelial Neoplasia | E6;E7 | Phase 1 | Engineered T-Cells | Cervical Intraepithelial Neoplasia |
NCT05066165 | NTLA-5001 in Subjects With Acute Myeloid Leukemia | Â | Phase 1/ Phase 2 | CAR T-Cells | Acute Myeloid Leukemia |
NCT03747965 | PD-1 Gene-knocked Out in Mesothelin-directed CAR-T Cells | PD-1 | Phase 1 | CAR T-Cells | Mesothelin Positive Multiple Solid Tumors |
NCT05643742 | A Safety and Efficacy Study Evaluating CTX112 | TRAC; β2M; CD70 | Phase 1/ Phase 2 | CAR T-Cells | B Cell-Malignancies |
NCT04502446 | A Safety and Efficacy Study Evaluating CTX130 | TRAC; β2M; CD70 | Phase 1 | CAR T-Cells | B Cell-Malignancies |
NCT03166878 | UCART019 in Patients With Relapsed or Refractory CD19 Tumors | TRAC;CD52 | Phase 1/ Phase 2 | CAR T-Cells | Leukemia and Lymphoma |
NCT05566223 | CISH Inactivated TILs in the Treatment of NSCLC | CISH | Phase 1/ Phase 2 | Engineered T-Cells | Non small cell lung cancer |
NCT05795595 | A Safety and Efficacy Study Evaluating CTX131 | TRAC; β2M; CD70 | Phase 1/ Phase 2 | CAR T-Cells | Renal cell carcinoma; Cervical Carcinoma; Pancreatic Adenocarcinoma; Malignant Pleural Mesothelioma |
NCT04035434 | A Safety and Efficacy Study Evaluating CTX110 | TRAC; β2M; CD70; | Phase 1/ Phase 2 | CAR T-Cells | B Cell-Malignancies |
NCT04426669 | CISH depletion using CRISPR/Cas9 in Tumor Infiltrating Lymphocytes | CISH | Phase 1/ Phase 2 | Engineered T-Cells | Gastrointestinal Cancer |
NCT05037669 | Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor | TCR, HLA-I; HLA-II | Phase 1 | CAR T-Cells | Acute Myeloid Leukemia; Chronic Lymphocytic Leukemia; Non Hodgkin Lymphoma |
NCT02863913 | PD-1 Knockout Engineered T Cells for Muscle-invasive Bladder Cancer | PD-1 | Phase 1 | Engineered T-Cells | Bladder Cancer |